Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Behind the Study: HER3: A Vital Target in Cancer Treatment

Oncotarget

October 12, 2023
Dr. Omkar Desai describes a research perspective he co-authored with Dr. Rui Wang that was published by Oncotarget in Volume 14, entitled, “HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.” continue reading »

Suppression of Cancer Stemness and Drug Resistance via BRAF/EGFR/MEK Inhibition in Colorectal Cancer Cells

News

October 11, 2023
PRESS RELEASE: On October 4, 2023, a new research paper was published in Oncotarget, entitled, “Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells.” continue reading »

STAT3 as a Target in H3K27M-mutant DMGs

News

October 9, 2023
PRESS RELEASE: On October 4, 2023, a new editorial perspective was published in Oncotarget, entitled, “STAT3 as a biologically relevant target in H3K27M-mutant diffuse midline glioma.” continue reading »

Genetic Insights into Early Breast Cancer in Kazakhstan

Oncotarget

October 5, 2023
In this new study, researchers aimed to determine the genetic predisposition to early breast cancer in women from Kazakhstan. continue reading »

UGDH in Clinical Oncology and Cancer Biology

News

October 4, 2023
PRESS RELEASE: On September 28, 2023, a new review was published in Oncotarget, entitled, “UDP-glucose dehydrogenase (UGDH) in clinical oncology and cancer biology.” continue reading »